消化系疾病患者血浆尿激酶型纤溶酶原激活物及其受体检测
出处
《中华血液学杂志》
CAS
CSCD
北大核心
2002年第9期495-495,共1页
Chinese Journal of Hematology
参考文献5
-
1Slot O,Brunner N,Locht H,et al.Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders:increased concentrations in rheumatoid arthritis[].Annals of the Rheumatic Diseases.1999
-
2Zhang LP,Takahara T,Yata Y,et al.Increased expression of plasminogen acivator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells[].Journal of Hepatology.1999
-
3Farinati F,Herszenyi L,Plebani M,et al.Increased levels of cathepsin B and L, urokinase-type plasminogen activator and its inhibitor type-1 as an early event in gastric carcinogenesis[].Carcinogenesis.1996
-
4Sier CF,Stephens R,Bizik J,et al.The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients[].Cancer Research.1998
-
5Kruger A,Soeltl R,Lutz V,et al.Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinasetype plasminogen activator receptor (CD87)[].Cancer Gene Therapy.2000
-
1刘怀深,吕喜英,兰桂云.结核性脑膜炎患者血清sIL-2R的检测分析[J].临床荟萃,2002,17(22):1343-1344. 被引量：3
-
2张巍巍,尹峰,甘天福.肝硬化患者血清中干扰素及受体检测的意义[J].医学检验与临床,2004,16(2):39-39.
-
3房芳,刘洁琳,刘雅,张维君,文杰,温绍君.肺栓塞患者溶栓前后纤溶因子的变化及意义[J].中华内科杂志,2007,46(9):768-769.
-
4李桂宾,孙玉红,高颖,王伟.良恶性胸水的实验室检查新进展[J].临床肺科杂志,2005,10(3):361-362. 被引量：6
-
5曾凤兰,张云.高血压病与血栓前状态的研究新进展[J].医学综述,2006,12(12):735-737. 被引量：2
-
6陈世义,付爱华,陈玉妨,张林,王桂兰,杜柏榕.可溶性白细胞介素2受体检测在结缔组织病中初步应用[J].中国免疫学杂志,1994,10(1):58-58. 被引量：2
-
7蔡后荣,沈国荣.可溶性白细胞介素2受体检测在肺部疾病中的临床意义[J].临床荟萃,1995,10(4):148-149.
-
8辛华,孙迪,李华.华支睾吸虫病20例患者血清中可溶性白细胞介素2受体检测的临床意义[J].黑龙江医药科学,2002,25(1):23-23.
-
9钱赓,易军,陈韵岱.单核细胞尿激酶型纤溶酶原激活物受体表达水平与冠状动脉粥样硬化斑块稳定性的关系[J].中华老年多器官疾病杂志,2010,9(2):123-126. 被引量：1
-
10刘彤,大桥胜,安江隆.PSS患者血管壁处组织型PA及其抑制因子的检测[J].中国皮肤性病学杂志,1994,8(1):3-4.
